How would you approach bone-only metastases in a postmenopausal woman with HR+/HER2+ breast cancer currently on anti-HER2+/AI maintenance?  

Initial treatment with Taxane-Trastuzumab-Pertuzumab with then maintenance with the two anti-HER2 agents and and an aromatase inhibitor. Would you biopsy new bone lesions? How would approach use of TDM-1 and/or changing endocrine backbone?



Answer from: Medical Oncologist at Academic Institution